XPG mRNA Expression Levels Modulate Prognosis in Resected Non-small-cell Lung Cancer in Conjunction With BRCA1 and ERCC1 Expression

Roberta Bartolucci; Jia Wei; Jose Javier Sanchez; Laia Perez-Roca; Imane Chaib; Francesco Puma; Raffaele Farabi; Pedro Mendez; Fausto Roila; Tatsuro Okamoto; Miquel Taron; Rafael Rosell


Clin Lung Cancer. 2009;10(1):47-52. 

In This Article


In summary, the present study validates the prognostic value of BRCA1 in early-stage NSCLC[8] and identifies XPG as a modulator of the risk of recurrence in patients with high BRCA1 mRNA levels. These findings could have important implications for the optimal use of adjuvant chemotherapy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.